

Digital Health Market: Focus on Digital Therapeutics (3rd Edition), 2023-2035: Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/DE2D0E331600EN.html>

Date: August 2023

Pages: 565

Price: US\$ 4,799.00 (Single User License)

ID: DE2D0E331600EN

Abstracts

The global digital therapeutics market is expected to be valued at USD 20 million by 2035 and anticipated to grow at a CAGR of 20% during the forecast period 2023-2035.

Digital Therapeutics (DTx) stands as an increasingly pivotal dimension within the sphere of digital health, offering a direct conduit for dispensing medical interventions targeted at the treatment, management, and prevention of diseases. These solutions pivot on evidence-based and clinically validated software or technologies that capture real-time

patient data, thereby heightening the effectiveness of treatments. With the ongoing digital transformation in healthcare, DTx has drawn significant attention from stakeholders and investors within the industry. Concurrently, governmental entities have taken proactive steps, enacting legislation, promulgating laws, and establishing regulations to oversee the burgeoning digital therapeutics sector.

For instance, the US Food and Drug Administration (USFDA) has initiated the Breakthrough Device Designation Program, aimed at expediting approvals for digital therapeutics. Noteworthy is the fact that as of September 2022, around 730 digital health products, spanning digital therapeutics, wellness applications, and digital biomarkers, had secured USFDA approval. Analogously, a parallel trend is observable in other nations like the UK, Germany, Denmark, and South Korea, where regulatory bodies have delineated specific protocols governing digital therapeutics and digital health solutions.

The sustained impetus within this market, coupled with the burgeoning demand for such solutions, is projected to drive market expansion throughout the envisaged forecast period.

Report Coverage

The study investigates the digital therapeutics market by examining various aspects such as the type of solution, therapy, purpose, business model, target therapeutic areas, and key geographical regions.

An analysis of factors impacting market growth, including drivers, restraints, opportunities, and challenges, is conducted within the report.

Assessment of potential advantages and obstacles within the market is offered, along with insights into the competitive environment for top market players.

Revenue forecasts for market segments are provided concerning six major regions.

A comprehensive report covers critical facets of the digital therapeutics market, starting with an introduction to digital therapeutics, elucidating their diverse types, primary healthcare applications, and recent advancements in the field.

The report delves into the market landscape, categorizing digital therapeutics

solutions based on development status, solution types, therapy purposes, targeted indications, therapeutic areas, and involved companies. This includes details such as establishment year, business model, and headquarters location of engaged companies.

Additionally, the report presents an in-depth analysis of market trends using schematic representations like bubble analysis, tree maps, and world maps, for comparing leading players, distribution across therapeutic areas, and regional presence.

A competitive analysis evaluates digital therapeutics for popular therapeutic areas, assessing product portfolios and specific parameters such as development status, therapy type, and prescription requirements.

Company profiles of large, mid-sized, and small players encompass overviews, product portfolios, recent developments, and future outlooks. This includes completed, ongoing, and planned clinical studies, funding analysis, partnership insights, business models, pricing strategies, and market forecasts for the digital therapeutics market until 2035, considering adoption trends, price variations, and market distribution.

Moreover, a focused evaluation of women's digital health solutions is presented, including developer details, current status, application areas, usage during pregnancy stages, and end-users.

Finally, the report discusses influential trends, drivers, and challenges employing a SWOT analysis, indicating their relative impact on the digital therapeutics industry.

Key Market Companies

Akili Interactive

Big Health

Dreem

Kaia Health

MindMaze

Omada Health

Pear Therapeutics

Vida Health

Voluntis

WellDoc

Wellthy Therapeutics

Contents

1. PREFACE

- 1.1. Introduction
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Frequently Asked Questions
- 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Digitization in the Healthcare Sector
- 3.3. Next-Generation Healthcare Solutions
- 3.4. Key Concepts Associated with Digital Health Solutions
 - 3.4.1. Cognitive Behavioral Therapy (CBT)
 - 3.4.2. Internet of Things (IoT)
 - 3.4.3. Big Data
 - 3.4.4. Artificial Intelligence (AI)
 - 3.4.5. Gamification
- 3.5. Overview of Digital Therapeutics
 - 3.5.1. Key Strategic Initiatives
 - 3.5.1.1. Digital Therapeutics Alliance (DTA)
 - 3.5.1.2. Personal Connected Health (PCH) Alliance
 - 3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
 - 3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
 - 3.5.1.5. National Health Service (NHS) Guidelines
 - 3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
 - 3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
 - 3.5.2.1. Discovery and Preclinical Phase
 - 3.5.2.2. Clinical Trials and Validation
 - 3.5.2.3. Negotiation Involving Insurance Providers / Payers
 - 3.5.2.4. Distribution and Marketing
- 3.6. Concluding Remarks

4. CURRENT MARKET LANDSCAPE

- 4.1. Chapter Overview
- 4.2. Digital Therapeutics: Overall Market Landscape
 - 4.2.1. Analysis by Status of Development
 - 4.2.2. Analysis by Type of Solution
 - 4.2.3. Analysis by Type of Therapy
 - 4.2.4. Analysis by Purpose of Solution
 - 4.2.5. Analysis by Target Indication
 - 4.2.6. Analysis by Therapeutic Area
 - 4.2.7. Analysis by Target Population
- 4.3. Digital Therapeutics: Additional Information
 - 4.3.1. Analysis by Requirement of Prescription
 - 4.3.2. Analysis by Duration of Course
 - 4.3.3. Analysis by Cost of Solution
- 4.4. Digital Therapeutics: List of Developers
 - 4.4.1. Analysis by Year of Establishment
 - 4.4.2. Analysis by Company Size
 - 4.4.3. Analysis by Type of Business Model
 - 4.4.4. Analysis by Location of Headquarters
- 4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
- 4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
- 4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
- 4.8. Analysis of Regional Activity (World Map Representation)

5. PRODUCT COMPETITIVENESS ANALYSIS

- 5.1. Chapter Overview
- 5.2. Assumptions / Key Parameter
- 5.3. Methodology
- 5.4. Key Therapeutic Areas
 - 5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
 - 5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
 - 5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders

5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders

5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders

5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas

6. COMPANY PROFILES

6.1. Chapter Overview

6.2. Akili Interactive

6.2.1. Company Overview

6.2.2. Product Portfolio

6.2.3. Recent Developments and Future Outlook

6.3. Big Health

6.3.1. Company Overview

6.3.2. Product Portfolio

6.3.3. Recent Developments and Future Outlook

6.4. dreem

6.4.1. Company Overview

6.4.2. Product Portfolio

6.4.3. Recent Developments and Future Outlook

6.5. Kaia Health

6.5.1. Company Overview

6.5.2. Product Portfolio

6.5.3. Recent Developments and Future Outlook

6.6. MindMaze

6.6.1. Company Overview

6.6.2. Product Portfolio

6.6.3. Recent Developments and Future Outlook

6.7. Omada Health

6.7.1. Company Overview

6.7.2. Product Portfolio

6.7.3. Recent Developments and Future Outlook

6.8. Pear Therapeutics

6.8.1. Company Overview

6.8.2. Product Portfolio

6.8.3. Recent Developments and Future Outlook

6.9. Vida Health

- 6.9.1. Company Overview
- 6.9.2. Product Portfolio
- 6.9.3. Recent Developments and Future Outlook
- 6.10. Voluntis
 - 6.10.1. Company Overview
 - 6.10.2. Product Portfolio
 - 6.10.3. Recent Developments and Future Outlook
- 6.11. WellDoc
 - 6.11.1. Company Overview
 - 6.11.2. Product Portfolio
 - 6.11.3. Recent Developments and Future Outlook
- 6.12. Wellthy Therapeutics
 - 6.12.1. Company Overview
 - 6.12.2. Product Portfolio
 - 6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

- 7.1. Chapter Overview
- 7.2. Scope and Methodology
- 7.3. Digital Therapeutics: Clinical Trial Analysis
 - 7.3.1. Analysis by Trial Registration Year
 - 7.3.2. Analysis by Trial Status
 - 7.3.3. Analysis by Trial Registration Year and Trial Status
 - 7.3.4. Analysis by Trial Phase
 - 7.3.5. Analysis by Type of Study
 - 7.3.6. Analysis by Study Design
 - 7.3.7. Analysis by Study Age
 - 7.3.8. Analysis by Gender of Patients
 - 7.3.9. Analysis of Patients Enrolled by Trial Registration Year
 - 7.3.10. Analysis by Type of Sponsor
 - 7.3.11. Analysis by Focus Area
 - 7.3.12. Analysis by Geography
 - 7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
 - 7.3.14. Analysis of Patients Enrolled by Geography
- 7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS

- 8.1. Chapter Overview
- 8.2. Type of Funding Models
- 8.3. Digital therapeutics: List of Funding and Investments
 - 8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
 - 8.3.2. Analysis of Funding Instances by Year
 - 8.3.3. Analysis of Amount Invested by Year
 - 8.3.4. Analysis by Type of Funding
 - 8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
 - 8.3.6. Analysis by Therapeutic Area
 - 8.3.7. Analysis by Geography
 - 8.3.8. Most Active Players: Analysis by Number of Instances
 - 8.3.9. Most Active Players: Analysis by Amount Raised
 - 8.3.10. Most Active Investors: Analysis by Number of Instances
- 8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS

- 9.1. Chapter Overview
- 9.2. Partnership Models
- 9.3. Digital Therapeutics: List of Partnerships and Collaborations
 - 9.3.1. Analysis by Year of Partnership
 - 9.3.2. Analysis by Type of Partnership
 - 9.3.2.1. Analysis by Year of Partnership and Type of Partnership
 - 9.3.2.2. Analysis by Type of Partnership and Company Size
 - 9.3.3. Analysis by Type of Partner
 - 9.3.3.1. Analysis by Year of Partnership and Type of Partner
 - 9.3.3.2. Analysis by Type of Partnership and Type of Partner
 - 9.3.3.3. Analysis by Type of Partner and Company Size
 - 9.3.4. Analysis by Type of Therapy
 - 9.3.4.1. Analysis by Type of Partnership and Type of Therapy
 - 9.3.4.2. Analysis by Type of Partner and Type of Therapy
 - 9.3.5. Analysis by Therapeutic Area
 - 9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
 - 9.3.5.2. Analysis by Type of Partner and Therapeutic Area
 - 9.3.6. Most Active Players: Analysis by Number of Partnerships
 - 9.3.7. Analysis by Geography
 - 9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY

- 10.1. Chapter Overview
- 10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
 - 10.2.1. Participation in Global Events
 - 10.2.2. Marketing on Social Media Platforms
 - 10.2.3. Marketing on Online / Print Media Platforms
 - 10.2.4. Undertaking Various Promotional Activities through Official Websites
 - 10.2.5. Adoption of Different Business Models
 - 10.2.5.1. B2C Business Model
 - 10.2.5.2. B2B Business Model
 - 10.2.5.2. B2B2C Business Model
 - 10.2.6. Undertaking Various Promotional Activities through Product Add-ons
- 10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS

- 11.1. Chapter Overview
- 11.2. Bowman Strategy Clock
 - 11.2.1. Two Dimensions of Bowman Strategy Clock
 - 11.2.2. Eight Positions on Bowman Strategic Clock
- 11.3. Roots Analysis Framework
 - 11.3.1. Methodology
 - 11.3.2. Theoretical Framework and Price Evaluation Hypothesis
 - 11.3.3. Results and Interpretation
 - 11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
 - 11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
 - 11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
 - 11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
 - 11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
 - 11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
 - 11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
 - 11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
- 11.4. Concluding Remarks

12. MARKET FORECAST

- 12.1. Chapter Overview
- 12.2. Forecast Methodology and Key Assumptions

- 12.3. Global Digital Therapeutics Market, 2022-2035
- 12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
 - 12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
 - 12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
 - 12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
 - 12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
 - 12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
 - 12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
 - 12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
- 12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
 - 12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
 - 12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
- 12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
 - 12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
 - 12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
- 12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
 - 12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
 - 12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
- 12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
 - 12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
 - 12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
 - 12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
 - 12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
 - 12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
 - 12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
 - 12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
 - 12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
 - 12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
- 12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
 - 12.9.1. Digital Therapeutics Market in North America, 2022-2035
 - 12.9.2. Digital Therapeutics Market in Europe, 2022-2035
 - 12.9.3. Digital Therapeutics Market in Asia, 2022-2035
 - 12.9.4. Digital Therapeutics Market in MENA, 2022-2035
 - 12.9.5. Digital Therapeutics Market in Latin America, 2022-2035

- 12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
- 12.10. Concluding Remarks

13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT

- 13.1. Introduction: Women Digital Health
- 13.2. Chapter Overview
- 13.3. Women's Digital Health: Product Pipeline
 - 13.3.1. Analysis by Type of Solution
 - 13.3.2. Analysis by Status of Development
 - 13.3.3. Analysis by Product Ratings
 - 13.3.4. Analysis by Application Area
 - 13.3.5. Analysis of Products by Different Stages of Pregnancy
 - 13.3.6. Analysis by Purpose of Solution
 - 13.3.7. Analysis by Type of End-Users
 - 13.3.8. Analysis by Type of Solution and Application Area
- 13.4. Women's Digital Health: Developer's Landscape
 - 13.4.1. Analysis by Year of Establishment
 - 13.4.2. Analysis by Company Size
 - 13.4.3. Analysis by Location of Headquarters (Region-wise)
 - 13.4.4. Analysis by Company Size and Region
 - 13.4.5. Analysis by Location of Headquarters (Country-Wise)
 - 13.4.6. Leading Players: Analysis by Number of Solutions
 - 13.4.7. Regional Landscape: Analysis by Type of Solution

14. SWOT ANALYSIS

- 14.1. Chapter Overview
- 14.2. Comparison of SWOT Factors
 - 14.2.1. Strengths
 - 14.2.2. Weaknesses
 - 14.2.3. Opportunities
 - 14.2.4. Threats
 - 14.2.5. Conclusion

15. EXECUTIVE INSIGHTS

- 15.1. Chapter Overview
- 15.2. Ampersand Health

- 15.2.1. Company Snapshot
- 15.2.2. Interview Transcript
- 15.3. Canary Health
 - 15.3.1. Company Snapshot
 - 15.3.2. Interview Transcript
- 15.4. Dnurse Technology
 - 15.4.1. Company Snapshot
 - 15.4.2. Interview Transcript
- 15.5. Embr Labs
 - 15.5.1. Company Snapshot
 - 15.5.2. Interview Transcript
- 15.6. Exosystems
 - 15.6.1. Company Snapshot
 - 15.6.2. Interview Transcript
- 15.7. Floreo
 - 15.7.1. Company Snapshot
 - 15.7.2. Interview Transcript
- 15.8. GAIA
 - 15.8.1. Company Snapshot
 - 15.8.2. Interview Transcript
- 15.9. Healios
 - 15.9.1. Company Snapshot
 - 15.9.2. Interview Transcript
- 15.10. JOGGO Health
 - 15.10.1. Company Snapshot
 - 15.10.2. Interview Transcript
- 15.11. metaMe Health
 - 15.11.1. Company Snapshot
 - 15.11.2. Interview Transcript
- 15.12. SelfBack
 - 15.12.1. Company Snapshot
 - 15.12.2. Interview Transcript
- 15.13. Somatix
 - 15.13.1. Company Snapshot
 - 15.13.2. Interview Transcript
- 15.14. Tilak Healthcare
 - 15.14.1. Company Snapshot
 - 15.14.2. Interview Transcript
- 15.15. Turnaround Health

- 15.15.1. Company Snapshot
- 15.15.2. Interview Transcript
- 15.16. Vida Health
 - 15.16.1. Company Snapshot
 - 15.16.2. Interview Transcript
- 15.17. Voluntis
 - 15.17.1. Company Snapshot
 - 15.17.2. Interview Transcript
- 15.18. Wellthy Therapeutics
 - 15.18.1. Company Snapshot
 - 15.18.2. Interview Transcript
- 15.19. Undisclosed
 - 15.19.1. Interview Transcript: Founder and Chief Executive Officer

16. CONCLUDING REMARKS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Digital Health Market: Focus on Digital Therapeutics (3rd Edition), 2023-2035: Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/DE2D0E331600EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DE2D0E331600EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970